Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: Case report and review of fluoropyrimidine-related cardiotoxicity

Oncology

Volumn 76, Issue 5, 2009, Pages 322-325

  Le Brun Ly, Valérie ^a,b   Martin, Jean ^a   Venat Bouvet, Laurence ^a   Darodes, Nicole ^b   Labourey, Jean Luc ^a   Genet, Dominique ^a   Tubiana Mathieu, Nicole ^a  

^a Departments of Oncology   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Capecitabine; Cardiac toxicity; Fluoropyrimidine

Indexed keywords

BISOPROLOL; CAPECITABINE; FLUOROPYRIMIDINE; GLYCERYL TRINITRATE; NAVELBINE; NICORANDIL; NITRIC ACID DERIVATIVE; PARACETAMOL; TRASTUZUMAB; VERAPAMIL;

ADULT; ANAMNESIS; ARM PAIN; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INJURY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKINESIA; LOADING DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PAIN; PRIORITY JOURNAL; PROPHYLAXIS; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEST PAIN; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; FEMALE; FLUOROURACIL; HUMANS; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; PROGNOSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 62649101147     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209336     Document Type: Article

References (48)

1. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
2. Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
3. Dent RG, McColl I: 5-fluorouracil and angina. Lancet 1975; 1: 347-348.
4. Tsavaris N, Kosmas C, Vadiaka M, et al: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy: a survey of 427 patients. Med Sci Monit 2002; 8:P151-P157.
5. Labianca R, Beretta G, Clerici M, et al: Symptomatic cardiotoxicity associated with 5-fluorouracil: a study on 1,083 patients. Tumori 1982; 68: 505-510.
6. Tsibiribi P, Descotes J, Lombard-Bohas C, et al: Cardiotoxicity of 5-fluorouracil in 1,350 patients with no prior history of heart disease. Bull Cancer 2006; 93:E27-E30.
7. Freeman NJ, Constanza ME: 5-fluorouracil associated cardiotoxicity. Cancer 1988; 61: 36-45.
8. Meyer CC, Calis KA, Burke LB, et al: Symptomatic cardiotoxicity associated with 5- fluorouracil. Pharmacotherapy 1997; 17: 729-736.
9. de Forni M, Malet-Martino MC, Jaillais P, et al: Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-1801.
10. Abele R, Alberto P, Kaplan S, et al: Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J Clin Oncol 1983; 1: 750-754.
11. Kikuchi K, Majima S, Murakami M: Clinical survey on cardiotoxicity of tegafur (FT-207): compilation of a nationwide survey (in Japanese). Gan To Kagaku Ryoho 1982; 9: 1482-1488.
12. Schnetzler B, Popova N, Collao Lamb C, et al: Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723-724.
13. Aksoy S, Karaca B, Dincer M, et al: Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother 2005; 39: 573-574.
14. Singer M: Cardiotoxicity and capecitabine: a case report. Clin J Oncol Nurs 2003; 7: 72-@ 75.
15. Bertolini A, Flumano M, Fusco O, et al: Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001; 87: 200-206.
16. Frickhofen N, Beck FJ, Jung B, et al: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797-801.
17. Camps C, Godes M, Soler JJ: Possible cardiotoxicity induced by orally administered fluoropyrimidines. An Med Interna 1990; 7: 525-527.
18. Rosati G, Cordio S, Tucci A, et al: A phase II trial of oxaliplatin (L-OHP) and uracil-tegafur (UFT)/folinic acid (FA) for advanced colorectal cancer (ACC) in elderly patents. ASCO Meet Abstr 2004:3681.
19. Meydan N, Kundak I, Tugba Y, et al: Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow- up. Jpn J Clin Oncol 2005; 35: 265-270.
20. Smith KL, Dang C, Seidman AD: Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006; 5: 619-629. 21 Hayes DF, Picard MH: Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006; 24: 4056-4058.
21. Akhtar S, Salim K, Bano Z: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-444.
22. Rezkalla S, Kloner RA, Ensley J, et al: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective clinical study. J Clin Oncol 1999; 7: 509-514.
23. Stevenson DL, Mikhailidis DP, Gillett DS: Cardiotoxicity of 5-fluorouracil. Lancet 1977; 2: 406-407.
24. Kuzel T, Esparaz B, Green D, Kies M: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65: 885-889.
25. Collins C, Weiden PL: Cardiotoxicity of 5- fluorouracil. Cancer Treat Rep 1987; 71: 733-736.
26. Patel B, Kloner RA, Ensley J, et al: 5-fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294: 238-243.
27. Levillain R: Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluourouacil. CR Séances Soc Biol Fil 1972; 166: 340-342.
28. Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30: 871-879.
29. Van Cutsem E, Hoff PM, Blum JL, et al: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13: 484-485.
30. Jensen SA, Sorensen JB: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487-493.
31. Kuppens IE, Boot H, Beijnen JH, et al: Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004; 140: 494-495.
32. Cianci G, Morelli MF, Cannita K, et al: Prophylactic options in patients with 5-fluorouracil- associated cardiotoxicity. Br J Cancer 2003; 88: 1507-1509.
33. Capecitabine prescribing information, 2006.
34. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110-1117.
35. Takahashi Y, Bucana CD, Liu W, et al: Platelet- derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-1151.
36. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen tension and pH on the expression of plateletderived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997; 57: 570-572.
37. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M: The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10: 805-818; discussion 819.
38. Mancuso L: Prinzmetal's angina during 5- fluorouracil chemotherapy. Am J Med 1987; 83: 602.
39. Mosseri M, Fingert HJ, Varticovski L, et al: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-3033.
40. Sudhoff T, Enderle MD, Pahlke M, et al: 5- fluorouracil induces arterial vasocontraction. Ann Oncol 2004; 15: 661-664.
41. Shoemaker LK, Arora U, Rocha Lima CM: 5-Fluorouracil induced coronary vasospasm. Cancer Control 2004; 11: 46-49.
42. Rizvi AA, Schauer P, Owlia D, et al: Capecitabine- induced coronary vasospasm: a case report. Angiology 2004; 55: 93-97.
43. Wardley A, et al: Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: primary efficacy results from a randomised phase II study (CHAT). ESMO 31st Congress, Istanbul (LBA6), presented October 2, 2006.
44. Xu L, Song S, Zhu J, et al: A phase II trial of trastuzumab (H) + capecitabine (X) as firstline treatment in patients (pts) with HER2- positive metastatic breast cancer (MBC). Ann Oncol 2006; 17 (suppl 9):ix76 (abstract 169P).
45. Lybaert W, Wildiers H, Neven P, et al: Multicentre phase II study of capecitabine (X), docetaxel (T) 8 trastuzumab (H) as neoadjuvant treatment for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy results. Ann Oncol 2006; 17 (suppl 9):ix73 (abstract 154P).
46. Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J: Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006; 26: 2451-2456.
47. Lorusso V, Spada M, Giampaglia M, et al: Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC): a phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 2006; 17(suppl 7): vii15-vii17.
48. Nole F, Catania C, Sanna G, et al: Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322-329.